Abstract：Objective] To explore clinical efficacy and safety of selegiline for the treatment of sleep disor‐der in early Parkinson disease(PD) .[Methods] Totally 90 patients with early PD treated by trihexyphenidyl , amantadine and vitamin E were randomly divided into selegiline group and estazolam group .On the basis of the unchanged dose of original drugs ,the former was additionally given selegiline tablet 5mg/d ,while the latter was additionally given estazolam 1mg/d .The course was 4 weeks .All patients were surveyed by Pittsburg sleep quality index(PSQI) questionnaire .The sleep condition before and after treatment was analyzed .Mean‐while ,routine laboratory indexes were detected before and after the addition of the drugs .The incidence of ad‐verse reaction was analyzed and compared .[Results] After treatment ,the PSQI score was significantly im‐proved ,and there was significant difference between before and after treatment( P<0 .01) .There was no sig‐nificant difference in PSQI score after treatment between selegiline group and estazolam group( P > 0 .05) . There were significant differences in the scores of 3 factors(sleep quality ,daytime function and hypnotic drug) in PSQI after treatment between two groups( P <0 .05) .The incidence of adverse reaction in selegiline group and estazolam group was 17 .8% and 36 .9% respectively ,and there was significant difference between two groups( P <0 .05) .The incidence of drowsiness and orthostatic hypotension in selegiline group was signifi‐cantly lower than that in estazolam group( P<0 .01) .[Conclusion]Selegiline for the treatment of sleep disor‐der in PD is safe and effective .Selegiline for reducing hypnotic drug and improving sleep quality of PD patients is obviously superior to estazolam ,so it is worthy of clinical promotion .
2014, Vol. 31 
